Kyntra Bio (KYNB) Q4 2025 earnings review
Leaner Operations, But Clinical Goalposts Are Shifting
Kyntra Bio has successfully completed its financial transformation, emerging from FY25 with a drastically reduced burn rate and a $109.4M cash pile extending its runway into 2028. Total operating expenses were slashed by 71% year-over-year. However, the operational survival story is now giving way to clinical reality. The company's lead oncology asset, FG-3246, posted an underwhelming 7.0-month median progression-free survival in its broader cohort, forcing management to pivot their narrative toward a specific patient subgroup. With revenue effectively evaporating to $1.3M in Q4, Kyntra is now a pure-play clinical bet with high execution risk.
🐂 Bull Case
The $109.4M balance secures funding into 2028, completely removing the near-term financing overhang and allowing the company to reach major interim readouts in 2026.
The FG-3180 companion diagnostic successfully showed a correlation with tumor response, providing a clear path to screen for high-probability responders in future Phase 2/3 trials.
🐻 Bear Case
Management previously stated 10 months of rPFS was required for commercial success. The overall cohort for the FG-3246 combo hit only 7.0 months, significantly narrowing the drug's addressable market to a specific 1-prior-ARPI subgroup.
The cash runway guidance currently excludes the estimated $50-$60M needed to run the Roxadustat Phase 3 trial. A lack of partnership will force Kyntra to self-fund, severely compressing their 2028 timeline.
⚖️ Verdict: ⚪
Neutral. Management executed the financial restructuring perfectly, but the mixed clinical data on their lead asset prevents a bullish rating. The pivot to a subgroup analysis is a classic biotech red flag that warrants caution.
Key Themes
Efficacy Goalpost Shift Contradicts Positive Narrative
Management has spent prior quarters stating that a radiographic progression-free survival (rPFS) of '10 months or greater' was required for FG-3246 to be commercially competitive. In this Q4 release, they proudly highlight a 10.1-month rPFS—but only for a narrow subgroup of patients with one prior ARPI therapy. The overall study cohort actually posted an rPFS of just 7.0 months. This specific data point sharply contradicts the company's broadly positive narrative and exposes a significant efficacy risk if the drug is tested in broader mCRPC populations.
FG-3180 Biomarker Innovation
A major technological bright spot is the validation of FG-3180, the companion 89Zr PET imaging agent. The ASCO GU data showed that higher tumor uptake of this agent was numerically associated with a PSA50 response (p=0.053). This innovation allows Kyntra to select patients with high CD46 expression, fundamentally changing trial economics by screening out non-responders and increasing the probability of clinical success.
Drastic Cost Structure Transformation
Following the sale of the FibroGen China business, Kyntra's operating expenses are now Stable at a much lower baseline. Total operating expenses for FY25 came in at $52.3M, a staggering deceleration from the $180.0M burned in FY24. Q4 R&D and SG&A expenses were tightly managed at ~$7.3M each, proving that the restructuring was successfully implemented.
Roxadustat Protocol Submitted
The company officially submitted the pivotal Phase 3 clinical trial protocol for roxadustat in lower-risk myelodysplastic syndromes (LR-MDS) to the FDA. With Orphan Drug Designation secured, this provides a clear regulatory path to commercialize a wholly-owned asset with 7 years of U.S. exclusivity.
Roxadustat Phase 3 Funding Overhang
While the protocol is submitted, a massive funding question remains. Management noted they are 'exploring the opportunity to develop roxadustat internally or with a strategic partner.' Previous transcripts indicated this trial will cost $50-$60M—a sum explicitly excluded from the 2028 cash runway guidance. If they fail to secure a partner, self-funding will drastically reverse their financial stability.
Revenue Evaporation
Total revenue from continuing operations decelerated to just $1.3M in Q4 25, down from $3.1M in the prior year. For the full year, continuing operations generated only $6.4M compared to $29.6M in 2024. Investors must treat Kyntra strictly as a pre-revenue, clinical-stage biotech that is entirely reliant on binary trial readouts.
Evolving Standard of Care in mCRPC (Macro Landscape)
The commercial landscape for metastatic castration-resistant prostate cancer is shifting rapidly with the mainstream adoption of radioligand therapies like Pluvicto. Management's strategic decision to restrict the Phase 2 trial to specific prior-therapy subgroups acknowledges this macro-industry shift. However, they are aiming at a moving target—if standard of care continues to evolve, their current trial design may face relevance challenges by its 2026 readout.
Other KPIs
Stable sequential decline from $121.1M in Q3 2025. The balance sheet remains heavily fortified by the proceeds of the FibroGen China divestiture earlier in the year. The current quarterly burn rate (Net Loss from continuing operations) is ~$14.6M, which mathematically supports the company's projection of a runway into 2028, assuming trial costs do not spike unexpectedly.
Accelerating improvement compared to the $153.1M net loss recorded in FY24. This equates to a loss of $14.40 per share versus $38.26 per share in the prior year, proving that the structural changes to overhead and headcount have sustainably reduced the corporate cash bleed.
Guidance
Stable. The company reiterates that current funds are sufficient to last into 2028. However, it is crucial to note that this assumes they do not self-fund the massive roxadustat Phase 3 trial.
Stable. Management reaffirmed the timeline for the critical dose optimization study readout, giving investors a clear 12-18 month holding period before the next major binary catalyst.
Decelerating. Prior quarters indicated the protocol would be submitted in Q4 2025 with rapid follow-up. Guiding for a trial start in the second half of 2026 suggests extended partnership negotiations or a slower-than-expected FDA feedback loop.
Key Questions
Phase 3 Funding Commitment
With the roxadustat Phase 3 trial expected to start in 2H 2026, what is the hard deadline to secure a partnership before you are forced to allocate your own balance sheet capital, thereby reducing the 2028 runway?
Efficacy Thresholds
You previously cited a 10-month rPFS goal for commercial competitiveness. Given the overall cohort in the combination study only reached 7.0 months, will you halt the FG-3246 program if the upcoming Phase 2 monotherapy interim data falls closer to the 7-month mark?
FG-3180 Diagnostic Economics
Assuming FG-3180 continues to show strong correlation with tumor response, are there plans to out-license the imaging agent separately, or will its value remain entirely tethered to the success of the FG-3246 ADC?